About | HeinOnline Law Journal Library | HeinOnline Law Journal Library | HeinOnline



80 Def. Counsel J. 1 (2013)

handle is hein.journals/defcon80 and id is 1 raw text is: January 2013
Volume 80, No. 1
Pages 1-112
International Association of Defense Counsel
303 West Madison
Suite 925
Chicago, IL 60606 USA
Telephone: 312.368.1494
Fax:       312.368.1854
E-mail:   info@iadclaw.org
Web site:  http://www.iadclaw.org
In this issue...
ANNOUNCEMENTS AND DEPARTMENTS
Table of Contents...........................................................  1
President's  Page.. ...........................................................3
IADC Tenets of Professionalism...............................................5
IAD C  O fficers  and  Board  of  Directors..........   ..........................................7
Defense Counsel Journal Board and Committee Vice Chairs...........................8
Calendar of Meetings........................................................10
Conning the Newsletters.........................    ......................... .....90
FEATURED ARTICLES
WILL THE REAL INTENDED
THIRD-PARTY PLEASE STAND UP?................................................11
By: Paul C Peterson and Ryan P Myers
Considering legal doctrines that have been found to provide non-clients with standing to sue an
attorney.
IN UNITY THERE IS STRENGTH: THE ADVANTAGES
(AND DISADVANTAGES) OF JOINT DEFENSE GROUPS.              ...........  ............29
By: Bradley C Nahrstadt and W Brandon Rogers
Discussing the advantages associated with forming a joint defense group, identifying possible risks
associated with a joint defense group, and discussing preservation of joint defense privilege.
THE EMERGING BATTLEFIELD: SHOULD THE USE OF A
NONMONOTONIC, NON-THRESHOLD DOSE-RESPONSE
CURVE FOR ALLEGED ENDOCRINE-DISRUPTING
CHEMICALS SURVIVE A DAUBERT/PRYE CHALLENGE ...........              .............45
By: Mark C Surprenant and Diana Cole Surprenant
Demonstrating how-to construct a successful Daubert/Frye challenge against an expert's attempted
use of a nonmonotonic, non-threshold dose-response curve to support an adverse causation
opinion.